No Data
No Data
Optimism for China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Has Grown This Past Week, Despite Five-year Decline in Earnings
When we invest, we're generally looking for stocks that outperform the market average. Buying under-rated businesses is one path to excess returns. For example, long term China Resources Boya Bio-ph
China Resources Pharmaceutical (03320): China Resources Liberal Arts Biotech's net profit for the first quarter of 152.2 million yuan decreased by 12.97% year-on-year
China Resources Pharmaceuticals (03320) announced that China Resources Biotech, a subsidiary of the company, will be 3 as of March 31, 2024...
Liberal Arts Biotech (300294.SZ) announced first-quarter results, net profit of 152 million yuan, a decrease of 10.74%
Liberal Arts Biotech (300294.SZ) released its report for the first quarter of 2024, achieving 4.4 operating income during the reporting period...
Retail Investors Are China Resources Boya Bio-pharmaceutical Group Co.,Ltd's (SZSE:300294) Biggest Owners and Were Rewarded After Market Cap Rose by CN¥837m Last Week
Key Insights Significant control over China Resources Boya Bio-pharmaceutical GroupLtd by retail investors implies that the general public has more power to influence management and governance-related
Liberal Arts Biotech (300294.SZ) plans to pay 3 yuan for 10 shares to be deducted from interest on April 26
Liberal Arts Biotech (300294.SZ) announced that the company's 2023 equity distribution plan: every 10...
Liberal Arts Biotech (300294.SZ): In 2023, the company's VIII factor and PCC sales trends were good, and overall sales grew rapidly
Gelonghui, April 2, 丨 Boya Biotech (300294.SZ) was surveyed by a specific target on April 1, 2024. Regarding “the sales situation of the company's factor VIII, PCC and other products,” the company replied that in 2023, the company's sales trend of Factor VIII and PCC was good, and overall sales were growing rapidly. According to hospital CPA sample statistics, the company's prothrombin complex (PCC) ranks third in the industry. The company attaches importance to building an academic system and continuously improving product coverage and penetration rate.
No Data